In the News

1855 News Items found
Pictured: Barbara Raphael & Chioma Enweasor
Learning Curve
Our summer fellowship program helps medical students learn to become physician-scientists. Read about one of our trainees who investigated an imaging tool for use in patients with a rare uterine cancer.
Pictured: Scott Lowe & Zhen Zhao
Video
Watch our scientists discuss how the Geoffrey Beene Center helped Memorial Sloan Kettering establish a progressive approach to modern cancer research.
Pictured: 2013 Graduates
Feature
Honors were conferred, PhD degrees were awarded, and a Pulitzer Prize-winning author addressed the graduates at the May 10 ceremony.
Pictured: Three-dimensional structure of the protein mTOR
In the Lab
In an eagerly awaited study, Memorial Sloan Kettering researchers report on the molecular structure of mTOR, a protein commonly mutated in cancer.
Pictured:  Timothy Chan
In the Lab
Investigators have sequenced the genome of adenoid cystic carcinoma, a rare and deadly head and neck cancer. The work sets the stage for the sequencing of additional rare cancers at Memorial Sloan Kettering.
Charles Sawyers, Kenneth Offit, and Larry Norton
Honors
Charles Sawyers, Larry Norton, and Kenneth Offit are being honored with special awards at the annual meeting of the world’s leading professional organization for cancer physicians and researchers.
Pictured: Siddhartha Mukherjee
Event
Physician-scientist Siddhartha Mukherjee, author of <em>The Emperor of All Maladies: A Biography of Cancer</em>, spoke to 2013 graduates of the “tenderness and tension” inherent in scientific discovery.
Pictured: Melanocytes
Snapshot
Memorial Sloan Kettering researchers have developed innovative ways to study some skin diseases, including melanoma skin cancer.
Pictured: Christopher Lima
Honors
Dr. Lima is one of 27 biomedical researchers in the country being named an HHMI investigator today. This elite group of scientists will receive approximately $150 million over the next five years.
Pictured: Charles Sawyers
In the Lab
Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.